-
Product Insights
NewNet Present Value Model: Checkpoint Therapeutics Inc’s Cosibelimab
Empower your strategies with our Net Present Value Model: Checkpoint Therapeutics Inc's Cosibelimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belrestotug in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belrestotug in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belrestotug in Refractory Multiple Myeloma Drug Details: EOS-448 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belrestotug in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belrestotug in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belrestotug in Recurrent Head And Neck Squamous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ESP-01 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ESP-01 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ESP-01 in Triple-Negative Breast Cancer (TNBC) Drug Details: ESP-01 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant Hydrochloride in Melanoma Drug Details: EOS-850 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant Hydrochloride in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Evalstotug in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evalstotug in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Evalstotug in Gastroesophageal (GE) Junction Carcinomas Drug Details: Evalstotug (BA-3071)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Evalstotug in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evalstotug in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Evalstotug in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Evalstotug in Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evalstotug in Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Evalstotug in Uveal Melanoma Drug Details: Evalstotug (BA-3071) is under development for...